10.47 USD
-0.05
0.48%
At close Jan 17, 4:00 PM EST
After hours
10.30
-0.17
1.62%
1 day
-0.48%
5 days
10.21%
1 month
14.80%
3 months
13.31%
6 months
8.84%
Year to date
13.93%
1 year
94.97%
5 years
-78.82%
10 years
-66.81%
 

About: Inogen Inc is a medical technology company that develops and manufactures portable oxygen concentrators used to deliver oxygen therapy to patients with chronic respiratory conditions. Its key product, the Inogen One system, is a lightweight alternative to traditional, stationary oxygen concentrator systems and oxygen tanks. The firm sells its products to home medical equipment providers and also rents products directly to patients. Internationally, It sells its products through distributors large gas companies, and home oxygen providers. It generates the majority of its revenue in the United States.

Employees: 834

0
Funds holding %
of 6,823 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

100% more call options, than puts

Call options by funds: $2.7M | Put options by funds: $1.36M

39% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 18

9% more capital invested

Capital invested by funds: $189M [Q2] → $205M (+$16.5M) [Q3]

2% more funds holding

Funds holding: 130 [Q2] → 132 (+2) [Q3]

0% more repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 39

9.25% less ownership

Funds ownership: 98.48% [Q2] → 89.22% (-9.25%) [Q3]

100% less funds holding in top 10

Funds holding in top 10: 1 [Q2] → 0 (-1) [Q3]

Research analyst outlook

We haven’t received any recent analyst ratings for INGN.

Financial journalist opinion

Based on 5 articles about INGN published over the past 30 days

Positive
Zacks Investment Research
5 days ago
Inogen Stock Gains Following Solid Preliminary Q4 Revenues
INGN's revenue growth in the fourth quarter is likely to have been boosted by continued robust adoption of its products.
Inogen Stock Gains Following Solid Preliminary Q4 Revenues
Neutral
Business Wire
1 week ago
Inogen Announces Preliminary Fourth Quarter and Full Year 2024 Revenue
GOLETA, Calif.--(BUSINESS WIRE)---- $INGN #AirwayClearance--Inogen Announces Preliminary Fourth Quarter and Full Year 2024 Revenue.
Inogen Announces Preliminary Fourth Quarter and Full Year 2024 Revenue
Positive
Zacks Investment Research
2 weeks ago
Inogen Stock Rises as FDA Clears SIMEOX 200 Airway Clearance Device
INGN announces FDA clearance for the SIMEOX 200 Airway Clearance Device.
Inogen Stock Rises as FDA Clears SIMEOX 200 Airway Clearance Device
Neutral
Business Wire
3 weeks ago
Inogen Receives FDA 510(k) Clearance for SIMEOX 200 Airway Clearance Device
GOLETA, Calif.--(BUSINESS WIRE)---- $INGN #AirwayClearance--Inogen Receives FDA 510(k) Clearance for SIMEOX 200 Airway Clearance Device.
Inogen Receives FDA 510(k) Clearance for SIMEOX 200 Airway Clearance Device
Positive
Zacks Investment Research
3 weeks ago
Here's Why You Should Retain Inogen Stock in Your Portfolio Now
Expanding product portfolio and high prospects for POC raise optimism for INGN stock.
Here's Why You Should Retain Inogen Stock in Your Portfolio Now
Neutral
Zacks Investment Research
1 month ago
The Zacks Analyst Blog Intuitive Surgical, Globus Medical, Glaukos, Veracyte and Inogen
Intuitive Surgical, Globus Medical, Glaukos, Veracyte and Inogen are included in this Analyst Blog.
The Zacks Analyst Blog Intuitive Surgical, Globus Medical, Glaukos, Veracyte and Inogen
Neutral
Zacks Investment Research
1 month ago
5 Medical Device Stocks That Survived the 2024 Market Volatility
Here, we discuss five medical device stocks, namely ISRG, GMED, GKOS, VCYT and INGN, which gained in 2024 despite ongoing challenges and provide an attractive investment opportunity for 2025.
5 Medical Device Stocks That Survived the 2024 Market Volatility
Positive
Zacks Investment Research
1 month ago
Inogen (INGN) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Inogen (INGN) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Inogen (INGN) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Positive
Zacks Investment Research
2 months ago
INGN Stock Gains Following Q3 Earnings Beat, Adjusted Gross Margin Up
Inogen's overall third-quarter 2024 results continue to gain from higher business-to-business sales.
INGN Stock Gains Following Q3 Earnings Beat, Adjusted Gross Margin Up
Neutral
Seeking Alpha
2 months ago
Inogen, Inc. (INGN) Q3 2024 Earnings Call Transcript
Call Start: 17:00 January 1, 0000 5:26 PM ET Inogen, Inc. (NASDAQ:INGN ) Q3 2024 Earnings Conference Call November 7, 2024, 5:00 PM ET Company Participants Ryan Peterson - Investor Relations Kevin Smith - President and CEO Mike Bourque - Chief Financial Officer Conference Call Participants Rohin Patel - JPMorgan Mike Matson - Needham Operator Welcome to Inogen's Third Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Inogen, Inc. (INGN) Q3 2024 Earnings Call Transcript
Charts implemented using Lightweight Charts™